Global Antifungal Therapeutics Market:Trends and Opportunities (2014-2019)
The report titled “Global Antifungal Therapeutics Market: Trends and Opportunities (2014-2019)” provides an in-depth analysis of global antifungal therapeutics market with focus on antifungal drug classes – Polyenes, Azoles, Echinocandins and Allylamines. It provides broad coverage of these classes with detailed analysis of drugs and indications in respective classes. It also assesses the key opportunities and underlying trends in the market and outlines the factors that are and will be driving the growth of the industry in the forecasted period (2014-19). Further, key players of the industry such as Merck & Co., Inc., Pfizer Inc., Astellas Pharma Inc. and Noble Corporation SCYNEXIS, Inc. are also profiled in the report.
Segment Coverage
Antifungal agents are drugs used for the treatment of fungal infections that can infect almost any part of the body including skin, nails, respiratory tract, urogenital tract and alimentary tract. Treatment of fungal infections currently available in the market can be broadly classified into four major classes of antifungal drugs – Polyenes, Azoles, Allylamines and Echinocandins. Global antifungal market is dominated by systemic antifungal infection.
Over the past several years, there have been high incidences of invasive fungal infections around the globe. In response to this, various antifungal agents with novel action mechanisms, broader action spectrum and fewer side effects have emerged. Growth within global antifungal therapeutics market is driven by high number of cases of fungal infections, rise in number of immune-compromised aged population and various government initiatives in this field. Some of the restraints to market’s growth are growing resistance to antifungal drugs, limitations with antifungal drugs, presence of generics and government regulations in pharmaceutical industry. Major trends prevailing in the industry includes growth in resistant strains and Candida & Aspergillus causing maximum fungal infections.
Segment Coverage
- Polyenes
- Azoles
- Echinocandins
- Allylamines
- Merck & Co., Inc.
- Pfizer Inc.
- Astellas Pharma Inc.
- SCYNEXIS Inc.
Antifungal agents are drugs used for the treatment of fungal infections that can infect almost any part of the body including skin, nails, respiratory tract, urogenital tract and alimentary tract. Treatment of fungal infections currently available in the market can be broadly classified into four major classes of antifungal drugs – Polyenes, Azoles, Allylamines and Echinocandins. Global antifungal market is dominated by systemic antifungal infection.
Over the past several years, there have been high incidences of invasive fungal infections around the globe. In response to this, various antifungal agents with novel action mechanisms, broader action spectrum and fewer side effects have emerged. Growth within global antifungal therapeutics market is driven by high number of cases of fungal infections, rise in number of immune-compromised aged population and various government initiatives in this field. Some of the restraints to market’s growth are growing resistance to antifungal drugs, limitations with antifungal drugs, presence of generics and government regulations in pharmaceutical industry. Major trends prevailing in the industry includes growth in resistant strains and Candida & Aspergillus causing maximum fungal infections.
1. EXECUTIVE SUMMARY
2. ANTIFUNGAL MARKET: AN INTRODUCTION
2.1 Fungal Infections
2.1.1 Fungal Infections: Types
2.2 Antifungal Treatment
3. GLOBAL ANTIFUNGAL THERAPEUTICS MARKET ANALYSIS
3.1 Global Antifungal Therapeutics Market Sizing
3.1.1 Global Antifungal Therapeutics Market Size (Actual & Forecasted)
3.2 Global Antifungal Therapeutics Market: Market Share Analysis
3.2.1 By Geography
3.2.2 By Organisms
3.2.3 Drug Class by Value
3.2.4 Drug Class by Volume
3.2.5 Drug Type by Value
3.2.6 Drug Type by Volume
4. GLOBAL ANTIFUNGAL THERAPEUTICS MARKET SEGMENT BY DRUG TYPE
4.1 Polyene Antifungal Drugs
4.1.1 Overview
4.1.2 Polyene Market Sizing (Actual & Forecasted)
4.2 Azoles Antifungal Drugs
4.2.1 Overview
4.2.2 Azoles Market Sizing (Actual & Forecasted)
4.2.3 Azoles Market Share by Drugs
4.3 Echinocandins Antifungal Drugs
4.3.1 Overview
4.3.2 Echinocandins Market Sizing (Actual & Forecasted)
4.3.3 Echinocandins Market Share by Drugs
4.4 Allylamines
4.4.1 Overview
5. GLOBAL ANTIFUNGAL MARKET: GROWTH DRIVERS & CHALLENGES
5.1 Growth Drivers
5.1.1 High Incidences of Serious Fungal Infections
5.1.2 Ageing Population
5.1.3 Government Initiatives
5.2 Challenges
5.2.1 Resistance to Antifungal Drugs
5.2.2 Government Regulation
5.2.3 Limitations Associated with Drugs Used for Treatments
5.2.4 Presence of Generics
6. GLOBAL ANTIFUNGAL MARKET TRENDS
6.1 Growth in Resistant Strains
6.2 Candida & Aspergillus Causing Maximum Fungal Infections
7. COMPETITIVE LANDSCAPE: GLOBAL ANTIFUNGAL MARKET
8. COMPANY PROFILES: GLOBAL ANTIFUNGAL MARKET
8.1 Merck & Co., Inc.
8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business Strategies
8.2 Pfizer Inc.
8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Business Strategies
8.3 Astellas Pharma Inc.
8.3.1 Business Overview
8.3.2 Financial Overview
8.3.3 Business Strategies
8.4 SCYNEXIS Inc.
8.4.1 Business Overview
8.4.2 Financial Overview
8.4.3 Business Strategies
2. ANTIFUNGAL MARKET: AN INTRODUCTION
2.1 Fungal Infections
2.1.1 Fungal Infections: Types
2.2 Antifungal Treatment
3. GLOBAL ANTIFUNGAL THERAPEUTICS MARKET ANALYSIS
3.1 Global Antifungal Therapeutics Market Sizing
3.1.1 Global Antifungal Therapeutics Market Size (Actual & Forecasted)
3.2 Global Antifungal Therapeutics Market: Market Share Analysis
3.2.1 By Geography
3.2.2 By Organisms
3.2.3 Drug Class by Value
3.2.4 Drug Class by Volume
3.2.5 Drug Type by Value
3.2.6 Drug Type by Volume
4. GLOBAL ANTIFUNGAL THERAPEUTICS MARKET SEGMENT BY DRUG TYPE
4.1 Polyene Antifungal Drugs
4.1.1 Overview
4.1.2 Polyene Market Sizing (Actual & Forecasted)
4.2 Azoles Antifungal Drugs
4.2.1 Overview
4.2.2 Azoles Market Sizing (Actual & Forecasted)
4.2.3 Azoles Market Share by Drugs
4.3 Echinocandins Antifungal Drugs
4.3.1 Overview
4.3.2 Echinocandins Market Sizing (Actual & Forecasted)
4.3.3 Echinocandins Market Share by Drugs
4.4 Allylamines
4.4.1 Overview
5. GLOBAL ANTIFUNGAL MARKET: GROWTH DRIVERS & CHALLENGES
5.1 Growth Drivers
5.1.1 High Incidences of Serious Fungal Infections
5.1.2 Ageing Population
5.1.3 Government Initiatives
5.2 Challenges
5.2.1 Resistance to Antifungal Drugs
5.2.2 Government Regulation
5.2.3 Limitations Associated with Drugs Used for Treatments
5.2.4 Presence of Generics
6. GLOBAL ANTIFUNGAL MARKET TRENDS
6.1 Growth in Resistant Strains
6.2 Candida & Aspergillus Causing Maximum Fungal Infections
7. COMPETITIVE LANDSCAPE: GLOBAL ANTIFUNGAL MARKET
8. COMPANY PROFILES: GLOBAL ANTIFUNGAL MARKET
8.1 Merck & Co., Inc.
8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business Strategies
8.2 Pfizer Inc.
8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Business Strategies
8.3 Astellas Pharma Inc.
8.3.1 Business Overview
8.3.2 Financial Overview
8.3.3 Business Strategies
8.4 SCYNEXIS Inc.
8.4.1 Business Overview
8.4.2 Financial Overview
8.4.3 Business Strategies
LIST OF FIGURES AND TABLES
Figure 1: Site of Action of the Common Antifungal Agents in Generalized Fungal Cell
Figure 2: Global Antifungal Therapeutics Market Size by Value, 2011-13 (US$ Billions)
Figure 3: Global Antifungal Therapeutics Market Size by Value Forecasted, 2014E-19E (US$ Billions)
Figure 4: Global Antifungal Therapeutics Market Share by Region (2012E)
Figure 5: Global Antifungal Market by Organisms Causing Fungal Infection (2013)
Figure 6: Global Antifungal Drug Class Market Share by Value (2013)
Figure 7: Global Antifungal Drug Class Market Share by Volume (2013)
Figure 8: Global Antifungal Drug Type Market Share by Value (2013)
Figure 9: Global Antifungal Drug Type Market Share by Volume (2013)
Figure 10: Structure of Some Common Polyene Antifungal Agents
Figure 11: Global Antifungal Class Polyene Market Size, 2011-13 (US$ Millions)
Figure 12: Global Antifungal Class Polyene Market Size Forecasted, 2014E-19E (US$ Millions)
Figure 13: Structure of Some Common Azoles Antifungal Agents
Figure 14: Global Antifungal Agent Azole Market Size by Drugs, 2011-13 (US$ Millions)
Figure 15: Global Antifungal Agent Azole Market Size Forecasted, 2014E-19E (US$ Millions)
Figure 16: Global Azoles Market Share by Drug Types (2013)
Figure 17: Structure of Some Common Echinocandins Antifungal Agents
Figure 18: Global Antifungal Agents Echinocandins Market Size by Drugs, 2011-13 (US$ Millions)
Figure 19: Global Antifungal Agents Echinocandins Market Size Forecasted, 2014E-19E (US$ Millions)
Figure 20: Global Echinocandins Market Share by Drug Types (2013)
Figure 21: Structure of Some Common Allylamines Antifungal Agents
Figure 22: Global Aging Population, 2005-13E (Millions)
Figure 23: Growth in Candida glabrata Resistant Strains, 2001-10
Figure 24: Growth in Aspergillus fumigatus Resistant Strains, 2001-10
Figure 25: Merck & Co., Inc. Revenue by Business Segment (2013)
Figure 26: Merck & Co., Inc. Antifungal Drugs (Cancidas & Noxafil) Revenue, 2010-13 (US$ Millions)
Figure 27: Pfizer Inc. Revenue by Business Segments (2013)
Figure 28: Pfizer Inc. Antifungal Drugs (Vfend & Diflucan) Revenue, 2011-13 (US$ Millions)
Figure 29: Astellas Pharma Inc. Sales by Geography (FY2013)
Figure 30: Astellas Pharma Inc. Antifungal Drugs (Funguard/Mycamine & AmBisome) Revenue, FY2010-FY2013 (US$ Millions)
Figure 31: SCYNEXIS, Inc. Revenue, FY2012-FY2013 (US$ Millions)
Table 1: Competitive Profile of Antifungal Drug Classes
Table 2: Overview of Polyenes Market
Table 3: Overview of Azoles Market
Table 4: Overview of Echinocandins Market
Table 5: Incidence of Serious Fungal Infections
Table 6: Fungal Patients in the US and ROW
Table 7: Antifungal Drugs in Development for Systemic Candiasis and Aspergillosis
Table 8: Competitive Landscape for Antifungal Agents
Table 9: Antifungal Drug Sales by Indication
Table 10: Global Sales of Select Antifungal Drugs
Figure 1: Site of Action of the Common Antifungal Agents in Generalized Fungal Cell
Figure 2: Global Antifungal Therapeutics Market Size by Value, 2011-13 (US$ Billions)
Figure 3: Global Antifungal Therapeutics Market Size by Value Forecasted, 2014E-19E (US$ Billions)
Figure 4: Global Antifungal Therapeutics Market Share by Region (2012E)
Figure 5: Global Antifungal Market by Organisms Causing Fungal Infection (2013)
Figure 6: Global Antifungal Drug Class Market Share by Value (2013)
Figure 7: Global Antifungal Drug Class Market Share by Volume (2013)
Figure 8: Global Antifungal Drug Type Market Share by Value (2013)
Figure 9: Global Antifungal Drug Type Market Share by Volume (2013)
Figure 10: Structure of Some Common Polyene Antifungal Agents
Figure 11: Global Antifungal Class Polyene Market Size, 2011-13 (US$ Millions)
Figure 12: Global Antifungal Class Polyene Market Size Forecasted, 2014E-19E (US$ Millions)
Figure 13: Structure of Some Common Azoles Antifungal Agents
Figure 14: Global Antifungal Agent Azole Market Size by Drugs, 2011-13 (US$ Millions)
Figure 15: Global Antifungal Agent Azole Market Size Forecasted, 2014E-19E (US$ Millions)
Figure 16: Global Azoles Market Share by Drug Types (2013)
Figure 17: Structure of Some Common Echinocandins Antifungal Agents
Figure 18: Global Antifungal Agents Echinocandins Market Size by Drugs, 2011-13 (US$ Millions)
Figure 19: Global Antifungal Agents Echinocandins Market Size Forecasted, 2014E-19E (US$ Millions)
Figure 20: Global Echinocandins Market Share by Drug Types (2013)
Figure 21: Structure of Some Common Allylamines Antifungal Agents
Figure 22: Global Aging Population, 2005-13E (Millions)
Figure 23: Growth in Candida glabrata Resistant Strains, 2001-10
Figure 24: Growth in Aspergillus fumigatus Resistant Strains, 2001-10
Figure 25: Merck & Co., Inc. Revenue by Business Segment (2013)
Figure 26: Merck & Co., Inc. Antifungal Drugs (Cancidas & Noxafil) Revenue, 2010-13 (US$ Millions)
Figure 27: Pfizer Inc. Revenue by Business Segments (2013)
Figure 28: Pfizer Inc. Antifungal Drugs (Vfend & Diflucan) Revenue, 2011-13 (US$ Millions)
Figure 29: Astellas Pharma Inc. Sales by Geography (FY2013)
Figure 30: Astellas Pharma Inc. Antifungal Drugs (Funguard/Mycamine & AmBisome) Revenue, FY2010-FY2013 (US$ Millions)
Figure 31: SCYNEXIS, Inc. Revenue, FY2012-FY2013 (US$ Millions)
Table 1: Competitive Profile of Antifungal Drug Classes
Table 2: Overview of Polyenes Market
Table 3: Overview of Azoles Market
Table 4: Overview of Echinocandins Market
Table 5: Incidence of Serious Fungal Infections
Table 6: Fungal Patients in the US and ROW
Table 7: Antifungal Drugs in Development for Systemic Candiasis and Aspergillosis
Table 8: Competitive Landscape for Antifungal Agents
Table 9: Antifungal Drug Sales by Indication
Table 10: Global Sales of Select Antifungal Drugs
